Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects

Pharmacogenomics

Volumn 14, Issue 15, 2013, Pages 1821-1831

  Kaniwa, Nahoko ^a,b   Sugiyama, Emiko ^a,b   Saito, Yoshiro ^a,b   Kurose, Kouichi ^a,b   Maekawa, Keiko ^a,b   Hasegawa, Ryuichi ^a,b   Furuya, Hirokazu ^b,c   Ikeda, Hiroko ^b,d   Takahashi, Yukitoshi ^b,d   Muramatsu, Masaaki ^b,e   Tohkin, Masahiro ^b,f   Ozeki, Takeshi ^g   Mushiroda, Taisei ^g   Kubo, Michiaki ^g   Kamatani, Naoyuki ^g   Abe, Masamichi ^b,h   Yagami, Akiko ^b,h   Ueta, Mayumi ^b,i   Sotozono, Chie ^b,i   Kinoshita, Shigeru ^b,i   Ikezawa, Zenro ^b,j   Matsunaga, Kayoko ^b,h   Aihara, Michiko ^b,j   more..

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b Research Group   (Japan)

^c Omuta National Hospital   (Japan)

^d SHIZUOKA INSTITUTE OF EPILEPSY AND NEUROLOGICAL DISORDERS   (Japan)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^f NAGOYA CITY UNIVERSITY   (Japan)

^g RIKEN   (Japan)

^h FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^j YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Aromatic antiepileptic drug; HLA A*02:07; HLA B*51:01; Phenobarbital; Phenytoin; Stevens Johnson syndrome; Toxic epidermal necrolysis; Zonisamide

Indexed keywords

AMOXICILLIN; CANDESARTAN HEXETIL; CARBAMAZEPINE; FAMOTIDINE; GABAPENTIN; HLA A ANTIGEN; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA DRB1 ANTIGEN; LANSOPRAZOLE; MINOCYCLINE; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; PIPERACILLIN PLUS TAZOBACTAM; TEMOZOLOMIDE; TIAPRIDE; VALPROIC ACID; VALSARTAN; ZONISAMIDE;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; EPILEPSY; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HLA A GENE; HLA B GENE; HLA DRB1 GENE; HLA GENE; HUMAN; INTRACTABLE EPILEPSY; JAPANESE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POPULATION GENETICS; POPULATION RESEARCH; PRESCHOOL CHILD; SCHOOL CHILD; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENOTYPE; HLA-DRB1 CHAINS; HUMANS; MALE; MIDDLE AGED; STEVENS-JOHNSON SYNDROME;

EID: 84893344987     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/PGS.13.180     Document Type: Article

References (38)

1. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch. Dermatol. 129(1), 92-96 (1993). (Pubitemid 23029676)
2. Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J. Dermatol. 24(11), 726-729 (1997).
3. Hashimoto K, Iijima M, Shiohara T et al. Toxic epidermal necrolysis. In: Handling Manual for Individual Severe Adverse Reactions (Volume 1). Japan Pharmaceutical Information Center, Tokyo, Japan, 21-35 (2007).
4. Rzany B, Mockenhaupt M, Baur S et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J. Clin. Epidemiol. 49(7), 769-773 (1996). (Pubitemid 26280728)
5. Mockenhaupt M, Viboud C, Dunant A et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J. Invest. Dermatol. 128(1), 35-44 (2008). (Pubitemid 350249390)
6. Chung WH, Hung SI, Hong HS et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428(6982), 486 (2004). • A promising genetic biomarker was detected for carbamazepine-induced Stevens-Johnson syndrome (SJS) in Han Chinese patients in Taiwan.
7. Wang Q, Zhou JQ, Zhou LM et al. Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland. Seizure 20(6), 446-448 (2011).
8. Zhang Y, Wang J, Zhao LM et al. Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. Eur. J. Clin. Pharmacol. 67(9), 885-887 (2011).
9. Man CB, Kwan P, Baum L et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 48(5), 1015-1018 (2007). (Pubitemid 46763406)
10. Mehta TY, Prajapati LM, Mittal B et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J. Dermatol. Venereol. Leprol. 75(6), 579-582 (2009).
11. Locharernkul C, Loplumlert J, Limotai C et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 49(12), 2087-2091 (2008).
12. Tassaneeyakul W, Tiamkao S, Jantararoungtong T et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 51(5), 926-930 (2010).
13. Lonjou C, Thomas L, Borot N et al. European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet. Genomics 18(2), 99-107 (2008). • Associations between HLA-B genotypes and SJS were found to be less strong in European individuals than in Han Chinese individuals in Taiwan.
14. Hung SI, Chung WH, Jee SH et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16(4), 297-306 (2006).
15. Hung SI, Chung WH, Liu ZS et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 11(3), 349-356 (2010). • HLA-B*15:02 is also associated with phenytoin- and oxcarbazepine-induced SJS/toxic epidermal necrolysis in Han Chinese patients in Taiwan.
16. Kaniwa N, Saito Y, Aihara M et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 51(12), 2461-2465 (2010).
17. Kim SH, Lee KW, Song WJ et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res. 97(1-2), 190-197 (2011).
18. Kashiwagi M, Aihara M, Takahashi Y et al. Human leukocyte antigen genotypes in carbamazepine-induced severe cutaneous adverse drug response in Japanese patients. J. Dermatol. 35(10), 683-685 (2008).
19. Ozeki T, Mushiroda T, Yowang A et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet. 20(5), 1034-1041 (2011). • HLA-A*31:01 was found to be a risk factor for carbamazepine-induced severe cutaneous adverse reactions in Japanese patients.
20. McCormack M, Alfirevic A, Bourgeois S et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364(12), 1134-1143 (2011). • HLA-A*31:01, another risk factor for carbamazepine-induced severe cutaneous adverse reactions, including SJS/toxic epidermal necrolysis, was found in European patients.
21. Hung SI, Chung WH, Liou LB et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102(11), 4134-4139 (2005).
22. Kang HR, Jee YK, Kim YS et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet. Genomics 21(5), 303-307 (2011).
23. Tassaneeyakul W, Jantararoungtong T, Chen P et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet. Genomics 19(9), 704-709 (2009).
24. Tohkin M, Kaniwa N, Saito Y et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J. 13(1), 60-69 (2013).
25. Martin AM, Nolan D, Gaudieri S et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl Acad. Sci. USA 101(12), 4180-4185 (2004). (Pubitemid 38405903)
26. Chantarangsu S, Mushiroda T, Mahasirimongkol S et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet. Genomics 19(2), 139-146 (2009).
27. Sudo C, Azuma Y, Maekawa K, Kaniwa N, Sai K, Saito Y. Current movement on four serious adverse events induced by medicinal drugs based on spontaneous reports in Japan. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku 129, 111-117 (2011).
28. Nakamura Y. The BioBank Japan Project. Clin. Adv. Hematol. Oncol. 5(9), 696-697 (2007). (Pubitemid 351699412)
29. Kitamura Y, Moriguchi M, Kaneko H et al. Determination of probability distribution of diplotype configuration (diplotype distribution) for each subject from genotypic data using the EM algorithm. Ann. Hum. Genet. 66(Pt 3), 183-193 (2002).
30. Kaniwa N, Hasegawa R. Exploratory studies on genetic biomarkers related to serious drug adverse reactions. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku 127, 1-14 (2009).
31. Saito S, Ota S, Yamada E, Inoko H, Ota M. Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population. Tissue Antigens 56(6), 522-529 (2000). (Pubitemid 32039363)
32. Middleton D, Menchaca L, Rood H. Komerofsky R. New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens 61(5), 403-407 (2003).
33. Shirato S, Kagaya F, Suzuki Y, Joukou S. Stevens-Johnson syndrome induced by methazolamide treatment. Arch. Ophthalmol. 115(4), 550-553 (1997). (Pubitemid 27172716)
34. Kim SH, Kim M, Lee KW et al. HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics 11(6), 879-884 (2010).
35. Her Y, Kil MS, Park JH, Kim CW, Kim SS. Stevens-Johnson syndrome induced by acetazolamide. J. Dermatol. 38(3), 272-275 (2011).
36. Wei CY, Chung WH, Huang HW et al. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J. Allergy Clin. Immunol. 129(6), 1562-1569 (2012).
37. Chen P, Lin JJ, Lu CS et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N. Engl. J. Med. 364(12), 1126-1133 (2011).
38. Ko TM, Chung WH, Wei CY et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J. Allergy Clin. Immunol. 128(6), 1266-1276 (2011).